Skip to main content
. 2020 Apr 14;183(3):471–479. doi: 10.1111/bjd.18857

Table 5.

Profile of treatment‐emergent adverse events related to investigational products

Event Minocycline 1%, n (%) Minocycline 3%, n (%) Vehicle, n (%)
Patients having at least one event 3 (3) 5 (5) 1 (1)
Nausea 0 (0) 1 (1) 0 (0)
Application site dermatitis 1 (1) 0 (0) 0 (0)
Application site erythema 0 (0) 1 (1) 0 (0)
Application site pruritus 1 (1) 1 (1) 0 (0)
Hypersensitivity 0 (0) 1 (1) 0 (0)
Headache 0 (0) 1 (1) 0 (0)
Rosacea 0 (0) 1 (1) 1 (1)
Urticaria 0 (0) 1 (1) 0 (0)